Tech Company Financing Transactions
Allink Biotherapeutics Funding Round
Allink Biotherapeutics, operating out of Shanghai, secured $42 million in funding from C&D Emerging Investment, Gaorong Capital and Legend Capital.
Transaction Overview
Company Name
Announced On
11/29/2024
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance: Global clinical development of lead candidates ALK201 and ALK202 through Phase 1 studies in Australia, the United States and China; Enrichment of current portfolio by developing multiple highly competitive new assets in oncology and immunology; Further development of its proprietary bispecific antibody and ADC technology platform; Global footprint expansion.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2nd Floor, South Building, No. 2966, Jinke Road, Pudong New
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Shanghai Allink Biotherapeutics Co., Ltd. established in 2023, is a pioneering biotechnology company specializing in bispecific antibody and antibody-drug conjugates (ADCs). The company's experienced R&D focuses on the discovery and clinical development of a diverse of FIC/BIC therapeutics.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/29/2024: Zenno Astronautics venture capital transaction
Next: 11/29/2024: Pathway Genomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs